Phage tablet and preparation method thereof

Through the combination of lyophilized protective agent and excipient, the problem of phages being easily inactivated in traditional preservation methods is solved, and phage tablets with high stability are prepared, which achieves long-term preservation and convenient transportation of phages, which are suitable for a wide range of applications.

CN118903032APending Publication Date: 2024-11-08WUHAN GRENON BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410934880.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-12
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Phages are prone to inactivate in traditional liquid storage methods, the lyophilization and storage process are complex and costly, and are sensitive to temperature, resulting in limited large-scale applications.

Method used

Using lyophilized protective agents (trehalose, skim milk powder, glycerin, flaxseed powder, glycine and arginine) combined with excipients (lactose, pregelated starch, sodium hydroxymethylcellulose and magnesium stearate), through The lyophilization and tableting process prepares high-stability phage tablets to ensure the activity and stability of phages during preservation and transportation.

Benefits of technology

It improves the stability and storage time of phages, simplifies storage and transportation, ensures the activity and effectiveness of phages, and is suitable for a wide range of applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004940993080000131
    Figure BDA0004940993080000131
  • Figure BDA0004940993080000141
    Figure BDA0004940993080000141
  • Figure BDA0004940993080000142
    Figure BDA0004940993080000142
Patent Text Reader

Abstract

The invention provides a bacteriophage tablet and a preparation method thereof, and the preparation method of the bacteriophage tablet comprises the following steps: S1, bacteriophage culture and collection: inoculating host bacteria into a liquid culture medium for culture, then inoculating bacteriophage for continuous culture, centrifuging after culture, and collecting the supernatant of the bacteriophage as a bacteriophage suspension; s2, preparation of a bacteriophage solution: mixing the bacteriophage suspension with a buffer solution to obtain the bacteriophage solution; s3, preparation of bacteriophage powder: uniformly mixing the bacteriophage solution with a freeze-drying protective additive, and freeze-drying to obtain the bacteriophage powder; the freeze-drying protective agent comprises the following components: trehalose, skim milk powder, glycerol, flaxseed powder, glycine and arginine. And S4, granulating, sieving and tabletting: mixing the bacteriophage powder with an excipient, granulating, sieving, and tabletting in a tablet press to obtain the bacteriophage tablet. The protective agent containing trehalose, skim milk powder, glycerol, flaxseed powder, glycine and arginine is added during freeze-drying, so that the aims of protecting the bacteriophage, maintaining the integrity and activity of the cell structure, preventing microbial contamination and prolonging the preservation period are fulfilled.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of bacteriophage, and in particular to a bacteriophage tablet and a preparation method thereof. Background Art

[0002] Bacteriophages are viruses that can specifically infect and lyse bacteria, which makes them an important research object in the field of antimicrobial biological agents. In recent years, with the increasing severity of the problem of antibiotic-resistant bacteria, the application prospects of bacteriophages in multiple fields such as agriculture, medicine and food safety have become increasingly broad. For example, in agriculture, bacteriophages are used to prevent and control plant diseases and increase crop yields; in the field of medicine, bacteriophages can be used as an alternative to antibiotics to treat a variety of bacterial infections, especially those that are difficult to cure due to drug resistance; in food processing and storage, bacteriophages can also be used to control food contamination and improve food safety. However, the storage and transportation methods of bacteriophages have always been a bottleneck problem restricting their large-scale application. Traditional liquid storage methods are prone to inactivation of bacteriophages, and freeze-dried storage can extend the shelf life, but the process is complicated and costly, and there is a risk of activity loss during rehydration. In addition, bacteriophages are sensitive to temperature, and long-term exposure to high temperature environments will significantly reduce their activity.

[0003] In order to solve the above problems, researchers have proposed a new idea of ​​making bacteriophages into tablets. Compared with liquid or freeze-dried forms, tablets have significant advantages: first, tablets can greatly improve the stability of bacteriophages and extend their shelf life; second, tablets do not need to be stored at low temperatures, making transportation and storage more convenient; third, tablets can accurately control the dosage used each time to ensure its effectiveness and consistency; finally, the tablet form is simple and easy to use, making it more convenient for users to take or apply. However, to successfully make bacteriophages into tablets and maintain their activity, a series of technical challenges must be overcome. This includes ensuring that bacteriophages are not inactivated by changes in pressure and temperature during the tableting process, and selecting suitable excipients to improve the stability of bacteriophages in tablets. Therefore, developing a tableting process that can maintain the activity and stability of bacteriophages has important practical application value. Summary of the invention

[0004] In view of this, the present invention provides a phage tablet capable of maintaining phage activity and stability and a preparation method thereof.

[0005] The technical solution of the present invention is implemented as follows: On the one hand, the present invention provides a method for preparing a bacteriophage tablet, comprising the following steps:

[0006] S1, phage culture and collection: the host bacteria are inoculated into a liquid culture medium for culture, and then the phage is inoculated and cultured. After the culture is completed, the phage is centrifuged and the phage supernatant is collected as a phage suspension;

[0007] S2, preparation of phage solution: mixing the phage suspension with the buffer to obtain a phage solution;

[0008] S3, preparation of phage powder: mixing the phage solution with a lyophilization protective agent and then lyophilizing to obtain phage powder; the components of the lyophilization protective agent include: trehalose, skim milk powder, glycerol, flaxseed powder, glycine and arginine;

[0009] S4, granulation, sieving, and tableting: the bacteriophage powder is mixed with the excipients and granulated, sieved, and then added to a tablet press for tableting to obtain bacteriophage tablets.

[0010] Trehalose in the freeze-drying protective agent can act as a cryoprotectant during the freezing process and a dehydration protective agent during the drying and dehydration process. It does not contain reducing groups, which can prevent the phage from undergoing protein browning reaction and thus deteriorating and inactivating. Skim milk powder is a polymer composite protective agent. During freeze drying, whey protein can form a protein film outside the bacteria to protect the phage. Flaxseed has a class of natural hydrophobic cyclic peptides - flaxseed cyclic peptides. Flaxseed cyclic peptides are cyclic peptides formed by the cyclization of 8 to 9 amino acids, with a molecular weight of approximately 960 to 1100 Da. Structurally, the cyclic structure and hydrophobic properties of flaxseed cyclic peptides have broad-spectrum and high-efficiency antibacterial activity, antioxidant effects, etc., which can inhibit other microorganisms in the environment to a certain extent, avoid pollution, and keep the phage active and pure during storage and application. Glycerol can prevent water from freezing at low temperatures. It can form hydrogen bonds with water, slow down the molecular movement of water, and thus avoid the formation of the same lattice between water molecules. In addition, the glycerol molecule itself has large polarity and polar groups, which can also resist the growth of ice crystals to a certain extent. Amino acids are the basic building blocks of proteins and have both acid and alkaline properties, which enables them to play a role in the cryopreservation and freeze-drying process of bacteriophages. Low concentrations of amino acids can prevent the denaturation of the phage protein coat by inhibiting the pH change caused by the crystallization of phosphate buffer salts. Glycine has a good filler effect. It can increase the collapse temperature of the finished product and prevent the destruction of the structure caused by collapse; it can also inhibit the crystallization of phosphate buffer salts during freezing and maintain pH stability, thereby avoiding the denaturation of phage coat proteins. Arginine has good acid and alkaline properties and can provide buffering protection during cryopreservation and drying to prevent protein denaturation caused by pH fluctuations.

[0011] These components complement each other and work together to protect the phage. Trehalose and glycerol provide protection under low temperature and dry conditions respectively, preventing ice crystal formation and maintaining the integrity of the cell structure. Skim milk powder and glycine work together to enhance the stability of the structure, the whey protein film provides a physical barrier, and glycine improves the physical stability and protective shell stability of the overall finished product. The cyclic peptides in flaxseed powder further prevent the phage from being contaminated by other microorganisms during production and storage, while enhancing the antioxidant capacity and protecting the kernel. Arginine and glycine work together to ensure that the phage activity is not interfered with by adverse external factors during freeze-drying and long-term storage by maintaining appropriate pH and environmental buffer stability.

[0012] On the basis of the above technical solution, preferably, in step S3, the mass ratio of phage solution to lyophilized protective agent is 1:1-1.5.

[0013] On the basis of the above technical scheme, preferably, in step S3, calculated by weight, the components of the lyoprotectant include 8 to 15 parts of trehalose, 10 to 20 parts of skimmed milk powder, 3 to 8 parts of glycerol, 1 to 2.5 parts of flaxseed powder, 0.5 to 3 parts of glycine and 0.5 to 3 parts of arginine.

[0014] On the basis of the above technical solution, preferably, in step S4, the amount of the excipient is 25% to 35% of the mass of the phage powder.

[0015] On the basis of the above technical solution, preferably, the components of the excipient include lactose, pregelatinized starch, sodium hydroxymethyl cellulose and magnesium stearate.

[0016] Specifically, lactose is a commonly used pharmaceutical filler that provides the volume and mass required for tablets, ensuring that each tablet contains an evenly distributed active ingredient (bacteriophage powder). At the same time, lactose has good compressibility, which helps to form tablets with suitable hardness and stable shape, and reduces the breakage or pulverization caused by transportation and storage. Pregelatinized starch has cohesiveness, which can bond powdered bacteriophages and other ingredients together to enhance the mechanical strength of the tablets. At the same time, pregelatinized starch has swelling properties in water and can be used as a disintegrant to ensure that the tablets can quickly disintegrate and release the active ingredients when they come into contact with liquid. CMC-Na (sodium hydroxymethylcellulose) is a disintegrant that helps the tablets to quickly disintegrate in the gastrointestinal tract, allowing the bacteriophages to be released and function as soon as possible. At the same time, CMC-Na also has stable physical and chemical properties, which can improve the stability of the tablets and prevent them from being deformed by moisture during preparation and storage. Magnesium stearate can reduce the friction of the tablets during tableting and prevent damage to the mold or tablet press. At the same time, the use of lubricants can improve the surface finish of the tablets and reduce adhesion between tablets.

[0017] Through the synergistic effect of these excipients, the phage tablet not only has good mechanical strength and tableting stability, but also can quickly disintegrate and release active phages after administration, thereby ensuring that it exerts the expected therapeutic effect.

[0018] On the basis of the above technical solution, preferably, calculated by weight, the components of the excipient include 25-35 parts of lactose, 10-20 parts of pregelatinized starch, 10-20 parts of sodium hydroxymethyl cellulose and 5-15 parts of magnesium stearate.

[0019] Based on the above technical solution, preferably, the volume ratio of phage suspension: buffer solution is 1:2-3.

[0020] On the basis of the above technical solution, preferably, the buffer comprises 40-60 mM Tris-HCl at pH 7.5, 90-110 mM NaCl, 25-15 mM MgSO4 and 0.01 wt% gelatin.

[0021] Tris-HCl has good buffering capacity, especially at pH 7.5. This pH value is close to the optimal activity range of most phages, so it can maintain the activity of phages and prevent protein structural denaturation and loss of function caused by pH changes. NaCl helps maintain osmotic pressure balance and electrolyte environment, simulating physiological conditions. The appropriate salt concentration can prevent the aggregation or precipitation of phage proteins and protect their structural and functional integrity. The MgSO4 content provides magnesium ions, which are essential for the replication and assembly of some phages. Magnesium ions can stabilize the secondary structure of phage nucleic acids and other biomacromolecules. Gelatin provides additional protein protection to prevent the denaturation and aggregation of phage proteins. As a protective agent, gelatin can simulate the natural environment to a certain extent and provide protection for phage proteins.

[0022] On the basis of the above technical solution, preferably, the freeze-drying method in step S3 comprises the following steps:

[0023] S31, pre-freezing: placing the sample in a freeze dryer, setting the temperature to -80°C, and maintaining the temperature for 1 h;

[0024] S32, freezing: heating to -50°C for 4 to 6 hours; then the freeze dryer maintains a vacuum of 0.3 to 1 mbar for 5 to 10 minutes;

[0025] S33, sublimation drying: continue heating to -10°C, heating time 1 to 1.5 hours, maintaining time 2 to 3 hours; heating to 0°C, heating time 1 to 1.5 hours, maintaining time 2 to 3 hours; heating to 5°C, heating time 1 to 1.5 hours, maintaining time 1 to 1.5 hours; heating to 15°C, heating time 2 to 2.5 hours, maintaining time 2 to 2.5 hours;

[0026] S34: analytical drying: heating to 20°C, heating time 1 to 1.5 hours, maintaining time 4 to 6 hours.

[0027] Gradually increasing the temperature can effectively convert ice crystals in the sample into gaseous water (sublimation process), preventing the existence of liquid water. The temperature is precisely controlled throughout the process to prevent the sample from being overheated, which may cause the phage to denature or inactivate.

[0028] At the same time, slow heating and gradual sublimation keep the structure of the sample as original as possible, preventing collapse and deformation, and ensuring the stability of the active ingredients of the bacteriophage.

[0029] On the other hand, the present invention also provides a bacteriophage tablet prepared by the above method.

[0030] The bacteriophage tablet and the preparation method thereof of the present invention have the following beneficial effects compared with the prior art:

[0031] (1) The present invention protects bacteriophages, maintains the integrity and activity of cell structures, prevents microbial contamination, and prolongs the shelf life by adding protective agents including trehalose, skim milk powder, glycerol, flaxseed powder, glycine and arginine during freeze-drying.

[0032] (2) The excipients containing lactose, pregelatinized starch, sodium hydroxymethyl cellulose and magnesium stearate are added during tableting of the present invention, which not only improves the mechanical strength and tableting stability of the tablets, but also enables rapid disintegration and release of active bacteriophages after administration, thereby ensuring that the expected therapeutic effect is achieved.

[0033] (3) The present invention uses a method of gradually increasing the temperature to keep the structure of the sample as original as possible, preventing collapse and deformation, thereby ensuring the stability of the active ingredients of the bacteriophage. DETAILED DESCRIPTION

[0034] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0035] The formula of the TSB liquid culture medium used in the present invention is: 17g of casein pancreatic digest, 3g of soy flour papain digest, 5g of sodium chloride, 2.5g of dipotassium hydrogen phosphate, 2.5g of glucose, 1000mL of purified water, pH 7.3±0.2, and it is used after being sterilized by pressure steam at 121°C.

[0036] Example 1

[0037] The preparation method of the bacteriophage tablet of this embodiment comprises the following contents:

[0038] S1, phage culture and collection: The host bacteria Escherichia coli DC543 was inoculated into TSB liquid medium and cultured with shaking for 12 h (the number of bacteria was about 10 10 / mL), and then inoculated with Escherichia coli phage DCP543, and continued to culture for 7h, centrifuged at 5000g for 10min, and collected the supernatant containing phage as phage suspension.

[0039] S2, preparation of phage solution: 100 mL of the phage suspension from step S1 was mixed with 260 mL of buffer to obtain a phage solution.

[0040] The buffer included 48 mM Tris-HCl at pH 7.5, 95 mM NaCl, 13 mM MgSO4 and 0.01 wt% gelatin.

[0041] S3, preparation of phage powder: 100 g of the phage solution of step S2 was mixed with 124 g of freeze-drying protective agent, and then placed on a shaker, shaken at 20°C and 220 rpm for 30 min until completely mixed; then placed in an empty freeze dryer to freeze-dry the phage to obtain phage powder.

[0042] The freeze-drying protective agent includes 110 g of trehalose, 130 g of skimmed milk powder, 55 parts of glycerol, 18 g of flaxseed powder, 25 g of glycine and 18 g of arginine.

[0043] The freeze-drying method comprises the following steps:

[0044] S31, pre-freezing: Place the phage solution and the lyophilization protective agent mixture in a sterile bottle and divide it into four trays, with the top tray containing 400mL, the second tray containing 800mL, the third tray containing 1000mL, and the fourth tray containing 1200mL. Place the tray on the freezing table, turn on the freeze-drying machine, adjust the refrigeration temperature to -80℃ for 1h, and the pre-freezing is completed;

[0045] S32, freezing: heating to -50°C, maintaining time for 5 hours; then the freeze dryer maintains vacuum at 0.7 mbar, maintaining time for 8 minutes;

[0046] S33, sublimation drying: continue heating to -10°C, heating time 1h, maintaining time 2.5h; heating to 0°C, heating time 1h, maintaining time 2.5h; heating to 5°C, heating time 1h, maintaining time 1.5h; heating to 15°C, heating time 2h, maintaining time 2.5h.

[0047] S34: analytical drying: heating to 20°C, heating time 1h, maintaining time 5h.

[0048] S4, granulation, sieving, tableting: 100 g of bacteriophage powder was mixed with 30 g of excipients, and then dry granulated into granules that could pass through an 18-mesh sieve, and then added to a tablet press for tableting. A shallow round mold of 11 mm was used for compression, and the target tablet weight was 421.65 mg, and the target hardness was 60 N. The components of the excipients included 30 g of lactose, 18 g of pregelatinized starch, 15 g of sodium hydroxymethylcellulose, and 13 g of magnesium stearate.

[0049] S5, the prepared phage tablets are sealed and packaged using sterile packaging materials to prevent contamination and maintain stability.

[0050] Example 2

[0051] A method for preparing a bacteriophage tablet comprises the following contents:

[0052] S1, phage culture and collection: The host bacteria Escherichia coli DC543 was inoculated into TSB liquid medium and cultured with shaking for 12 h (the number of bacteria was about 10 10 / mL), and then inoculated with Escherichia coli phage DCP543, and continued to culture for 7h, centrifuged at 5000g for 10min, and collected the supernatant containing phage as phage suspension.

[0053] S2, preparation of phage solution: 100 mL of the phage suspension from step S1 was mixed with 200 mL of buffer to obtain a phage solution.

[0054] The buffer included 40 mM Tris-HCl, pH 7.5, 110 mM NaCl, 10 mM MgSO4 and 0.01 wt% gelatin.

[0055] S3, preparation of phage powder: 100 g of the phage solution of step S2 was mixed with 100 g of freeze-drying protective agent, and then placed on a shaker, shaken at 20°C and 220 rpm for 30 min until completely mixed; then placed in an empty freeze dryer to freeze-dry the phage to obtain phage powder.

[0056] The freeze-drying protective agent includes 150 g of trehalose, 100 g of skimmed milk powder, 80 parts of glycerol, 25 g of flaxseed powder, 30 g of glycine and 5 g of arginine.

[0057] The freeze-drying method comprises the following steps:

[0058] S31, pre-freezing: Place the phage solution and the lyophilization protective agent mixture in a sterile bottle and divide it into four trays, with the top tray containing 400mL, the second tray containing 800mL, the third tray containing 1000mL, and the fourth tray containing 1200mL. Place the tray on the freezing table, turn on the freeze-drying machine, adjust the refrigeration temperature to -80℃ for 1h, and the pre-freezing is completed;

[0059] S32, freezing: heating to -50°C, maintaining time for 4 hours; then the freeze dryer maintains vacuum at 1 mbar, maintaining time for 5 minutes;

[0060] S33, sublimation drying: continue heating to -10°C, heating time 1.5h, maintaining time 2h; heating to 0°C, heating time 1h, maintaining time 2h; heating to 5°C, heating time 1h, maintaining time 1h; heating to 15°C, heating time 2.5h, maintaining time 2h.

[0061] S34: analytical drying: heating to 20°C, heating time 1.5h, maintaining time 4h.

[0062] S4, granulation, sieving, tableting: 100 g of bacteriophage powder was mixed with 25 g of excipients, and then dry granulated into granules that could pass through an 18-mesh sieve, and then added to a tablet press for tableting. A shallow round mold of 11 mm was used for compression, and the target tablet weight was 421.65 mg, and the target hardness was 60 N. The components of the excipients included 25 g of lactose, 20 g of pregelatinized starch, 10 g of sodium hydroxymethylcellulose, and 5 g of magnesium stearate.

[0063] S5, the prepared phage tablets are sealed and packaged using sterile packaging materials to prevent contamination and maintain stability.

[0064] Example 3

[0065] A method for preparing a bacteriophage tablet comprises the following contents:

[0066] S1, phage culture and collection: The host bacteria Escherichia coli DC543 was inoculated into TSB liquid medium and cultured with shaking for 12 h (the number of bacteria was about 10 10 / mL), and then inoculated with Escherichia coli phage DCP543, and continued to culture for 7h, centrifuged at 5000g for 10min, and collected the supernatant containing phage as phage suspension.

[0067] S2, preparation of phage solution: 100 mL of the phage suspension from step S1 was mixed with 300 mL of buffer to obtain a phage solution.

[0068] The buffer included 60 mM Tris-HCl, pH 7.5, 90 mM NaCl, 15 mM MgSO4 and 0.01 wt% gelatin.

[0069] S3, preparation of phage powder: 100 g of the phage solution in step S2 was mixed with 150 g of a freeze-drying protective agent, and then placed on a shaker, shaken at 20°C and 220 rpm for 30 min until completely mixed; then placed in an empty freeze dryer to freeze-dry the phage to obtain phage powder.

[0070] The freeze-drying protective agent includes 80g of trehalose, 200g of skimmed milk powder, 30 parts of glycerol, 10g of flaxseed powder, 5g of glycine and 30g of arginine.

[0071] The freeze-drying method comprises the following steps:

[0072] S31, pre-freezing: Place the phage solution and the lyophilization protective agent mixture in a sterile bottle and divide it into four trays, with the top tray containing 400mL, the second tray containing 800mL, the third tray containing 1000mL, and the fourth tray containing 1200mL. Place the tray on the freezing table, turn on the freeze-drying machine, adjust the refrigeration temperature to -80℃ for 1h, and the pre-freezing is completed;

[0073] S32, freezing: heating to -50°C, maintaining for 6 hours; then the freeze dryer maintains a vacuum of 0.3 mbar, maintaining for 10 minutes;

[0074] S33, sublimation drying: continue heating to -10°C, heating time 1h, maintaining time 3h; heating to 0°C, heating time 1.5h, maintaining time 3h; heating to 5°C, heating time 1.5h, maintaining time 1.5h; heating to 15°C, heating time 2h, maintaining time 2.5h.

[0075] S34: analytical drying: heating to 20°C, heating time 1h, maintaining time 6h.

[0076] S4, granulation, sieving, tableting: 100 g of bacteriophage powder was mixed with 35 g of excipients, and then dry granulated into granules that could pass through an 18-mesh sieve, and then added to a tablet press for tableting. A shallow round mold of 11 mm was used for compression, and the target tablet weight was 421.65 mg, and the target hardness was 60 N. The components of the excipients included 15 g of lactose, 10 g of pregelatinized starch, 20 g of sodium hydroxymethylcellulose, and 15 g of magnesium stearate.

[0077] S5, the prepared phage tablets are sealed and packaged using sterile packaging materials to prevent contamination and maintain stability.

[0078] Example 4

[0079] A method for preparing a bacteriophage tablet comprises the following contents:

[0080] S1, phage culture and collection: The host bacteria Escherichia coli DC543 was inoculated into TSB liquid medium and cultured with shaking for 12 h (the number of bacteria was about 10 10 / mL), and then inoculated with Escherichia coli phage DCP543, and continued to culture for 7h, centrifuged at 5000g for 10min, and collected the supernatant containing phage as phage suspension.

[0081] S2, preparation of phage solution: 100 mL of the phage suspension from step S1 was mixed with 220 mL of buffer to obtain a phage solution.

[0082] The buffer included 45 mM Tris-HCl at pH 7.5, 105 mM NaCl, 11 mM MgSO4 and 0.01 wt% gelatin.

[0083] S3, preparation of phage powder: 100 g of the phage solution in step S2 was mixed with 115 g of a freeze-drying protective agent, and then placed on a shaker, shaken at 20°C and 220 rpm for 30 min until completely mixed; then placed in an empty freeze dryer to freeze-dry the phage to obtain phage powder.

[0084] The freeze-drying protective agent includes 90 g of trehalose, 190 g of skimmed milk powder, 40 parts of glycerol, 23 g of flaxseed powder, 10 g of glycine and 20 g of arginine.

[0085] The freeze-drying method comprises the following steps:

[0086] S31, pre-freezing: Place the phage solution and the lyophilization protective agent mixture in a sterile bottle and divide it into four trays, with the top tray containing 400mL, the second tray containing 800mL, the third tray containing 1000mL, and the fourth tray containing 1200mL. Place the tray on the freezing table, turn on the freeze-drying machine, adjust the refrigeration temperature to -80℃ for 1h, and the pre-freezing is completed;

[0087] S32, freezing: heating to -50°C for 4.5 hours; then the freeze dryer maintains a vacuum of 0.8 mbar for 8 minutes;

[0088] S33, sublimation drying: continue heating to -10°C, heating time 70min, maintaining time 3h; heating to 0°C, heating time 80min, maintaining time 3h; heating to 5°C, heating time 65min, maintaining time 1h; heating to 15°C, heating time 2h, maintaining time 2h.

[0089] S34: analytical drying: heating to 20°C, heating time 65min, maintaining time 4.5h.

[0090] S4, granulation, sieving, tableting: 100 g of bacteriophage powder was mixed with 28 g of excipients, and then dry granulated into granules that could pass through an 18-mesh sieve, and then added to a tablet press for tableting. A shallow round mold of 11 mm was used for compression, and the target tablet weight was 421.65 mg, and the target hardness was 60 N. The components of the excipients included 23 g of lactose, 12 g of pregelatinized starch, 18 g of sodium hydroxymethylcellulose, and 6 g of magnesium stearate.

[0091] S5, the prepared phage tablets are sealed and packaged using sterile packaging materials to prevent contamination and maintain stability.

[0092] Comparative Example 1

[0093] Compared with Example 1, Comparative Example 1 lacks flaxseed powder in the freeze-dried protective agent, and the rest of the contents are the same.

[0094] Comparative Example 2

[0095] Compared with Example 1, the lyophilized protective agent in Comparative Example 2 lacks arginine, and the rest of the contents are the same.

[0096] Comparative Example 3

[0097] Compared with Example 1, Comparative Example 3 lacks glycine in the lyophilization protective agent, and the rest of the contents are the same.

[0098] Comparative Example 4

[0099] Comparative Example 4 is different from Example 1 in the sublimation drying method, and the rest of the contents are the same. The sublimation drying method is as follows: continue to heat to -10°C, heating time 1h, maintaining time 3h; heat to 15°C, heating time 2h, maintaining time 2.5h.

[0100] Using the phage suspension as a control, the phage tablets and suspension were monitored for one year to observe the changes in their potency. The preservation effect was tested by double-layer plate method: the preservation tube was mixed with the original volume of 0.1mL buffer, and 0.1g of each group was also taken, and diluted tenfold with buffer, and 0.1mL was taken from each tube, and 0.9mL of host bacterial solution (bacterial concentration>10 4 / mL), mixed well, cultured at 37°C overnight, then took an appropriate volume of 0.1mL of phage solution and host bacterial solution, mixed them, added TSB semi-solid medium, poured into double-layer plates, cultured at 37°C overnight, counted the phage plaques, and repeated the operation 3 times for each sample.

[0101] Table 1 Stability and activity of the tablets of Example 1

[0102]

[0103]

[0104] As shown in Table 1, the activity of the bacteriophages in the tablets prepared by the present invention was higher than that in the bacterial suspension when stored at 4°C, 25°C and 37°C, and the bacteriophage titer increased from 5×10 10 Reduced to 4.07×10 10 , the activity still remains above 80%, indicating that the compressed tablets prepared by the present invention can maintain a high activity of bacteriophage under long-term storage.

[0105] The following is a comparison of the activity and friability of the tablets prepared in the examples and comparative examples. The initial potency is 5×10 10 PFU / g, stored at 4℃ and 37℃ for 1 year respectively, and the phage activity inside the tablets was detected. The results are shown in Table 2.

[0106] Friability test: According to the 2020 edition of the Chinese Pharmacopoeia, for tablets weighing 0.65g or less, take a number of tablets to make the total weight about 6.5g, randomly select 32 tablets from the same batch of tablets, 16 tablets in a group, blow off the powder on the tablets, weigh accurately, put them in a cylinder, rotate 100 times, take them out, blow off the powder on the tablets, and weigh accurately.

[0107] Calculate the weight loss: % = (W1-W2) / W1×100%,

[0108] Where: W1-the first precision weighing weight; W 2- Weigh the weight accurately for the second time.

[0109] Result judgment: The weight loss should not exceed 0.8%, and no broken, cracked or crushed pieces should be detected to be qualified. Generally, only one test is performed. If the weight loss exceeds 0.8%, it should be repeated twice. The average weight loss of the three tests should not exceed 0.8%, and no broken, cracked or crushed pieces should be detected to be qualified.

[0110] Table 2 Comparison of tablet activity

[0111]

[0112]

[0113] As shown in Table 2, the tablets prepared in Examples 1 to 4 have higher stability and activity than the comparative examples, and Example 4 has the best effect. From Comparative Examples 1 to 3, it can be seen that the flaxseed powder, glycine and arginine in the freeze-drying protective agent have a positive effect on the stability and activity of the tablets. From Comparative Example 4, it can be seen that the gradual heating method can ensure the stability of the bacteriophage active ingredients and achieve the effect of extending the shelf life.

[0114] The tableting process for producing phage tablets provided by the present invention not only improves the storage stability and transportation convenience of phage, but also provides effective technical support for the wide application of phage. In actual operation, the tableting process can be appropriately adjusted according to the type of phage, activity requirements and specific use of the tablets. For example, for phage tablets that need to be stored for a long time, a packaging material with good moisture-proof performance can be selected.

[0115] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for preparing a bacteriophage tablet, characterized in that: The following steps are involved: S1, phage culture and collection: the host bacteria are inoculated into a liquid culture medium for culture, and then the phage is inoculated and cultured. After the culture is completed, the phage is centrifuged and the phage supernatant is collected as a phage suspension; S2, preparation of phage solution: mixing the phage suspension with the buffer to obtain a phage solution; S3, preparation of phage powder: mixing the phage solution with a lyophilization protective agent and then lyophilizing to obtain phage powder; the components of the lyophilization protective agent include: trehalose, skim milk powder, glycerol, flaxseed powder, glycine and arginine; S4, granulation, sieving, and tableting: the bacteriophage powder is mixed with the excipients and granulated, sieved, and then added to a tablet press for tableting to obtain bacteriophage tablets.

2. The method for preparing a bacteriophage tablet according to claim 1, characterized in that: In step S3, the mass ratio of phage solution to lyophilized protective agent is 1:1 to 1.

5.

3. The method for preparing a bacteriophage tablet according to claim 2, characterized in that: In step S3, the components of the lyoprotectant include 8 to 15 parts of trehalose, 10 to 20 parts of skimmed milk powder, 3 to 8 parts of glycerol, 1 to 2.5 parts of flaxseed powder, 0.5 to 3 parts of glycine and 0.5 to 3 parts of arginine, calculated by weight.

4. The method for preparing a bacteriophage tablet according to claim 1, characterized in that: In step S4, the amount of the excipient is 25% to 35% of the mass of the phage powder.

5. The method for preparing a bacteriophage tablet according to claim 4, characterized in that: The components of the excipient include lactose, pregelatinized starch, sodium hydroxymethylcellulose and magnesium stearate.

6. The method for preparing a bacteriophage tablet according to claim 5, characterized in that: Calculated by weight, the components of the excipient include 25-35 parts of lactose, 10-20 parts of pregelatinized starch, 10-20 parts of sodium hydroxymethyl cellulose and 5-15 parts of magnesium stearate.

7. The method for preparing a bacteriophage tablet according to claim 1, characterized in that: The volume ratio of phage suspension: buffer is 1:2-3.

8. The method for preparing a bacteriophage tablet according to claim 7, characterized in that: The buffer comprises 40-60 mM Tris-HCl at pH 7.5, 90-110 mM NaCl, 10-15 mM MgSO4 and 0.01 wt% gelatin.

9. The method for preparing a bacteriophage tablet according to claim 1, characterized in that: The freeze-drying method in step S3 comprises the following steps: S31, pre-freezing: placing the sample in a freeze dryer, setting the temperature to -80°C, and maintaining the temperature for 1 h; S32, freezing: heating to -50°C for 4 to 6 hours; then the freeze dryer maintains a vacuum of 0.3 to 1 mbar for 5 to 10 minutes; S33, sublimation drying: continue heating to -10°C, heating time 1 to 1.5 hours, maintaining time 2 to 3 hours; heating to 0°C, heating time 1 to 1.5 hours, maintaining time 2 to 3 hours; heating to 5°C, heating time 1 to 1.5 hours, maintaining time 1 to 1.5 hours; heating to 15°C, heating time 2 to 2.5 hours, maintaining time 2 to 2.5 hours; S34: analytical drying: heating to 20°C, heating time 1 to 1.5 hours, maintaining time 4 to 6 hours.

10. A bacteriophage tablet, characterized in that: The method is prepared by any one of claims 1 to 9.